The U.S. Food and Drug Administration is approving more novel pharmaceutical drugs based on single clinical trials and with less public disclosure about those trials than was the norm just a few years ago, a pair of recent ...
Aug 24, 2023
1
99
The U.S. Food & Drug Administration has approved Akeega (niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate cancer.
Aug 18, 2023
0
2
The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.
Aug 16, 2023
0
1
A new digital headset designed to measure alterations in brain function could change decisions about how quickly an athlete is ready to return to play after a concussion. In an evaluation of the device, UC San Francisco researchers ...
Aug 12, 2023
0
46
Karen Butcher, whose son died in 2020 of an opioid overdose, asked a panel of experts on Monday in Frankfort: If cost wasn't a factor, why shouldn't Kentucky explore the use of an illicit psychedelic drug as a treatment for ...
Jul 23, 2023
1
35
The US drug regulator gave full approval to a new Alzheimer's medicine on Thursday, a move that makes it more widely available to the public through government-run health insurance for the elderly.
Jul 7, 2023
0
3
The U.S. Food and Drug Administration has approved Litfulo (ritlecitinib) for adults and adolescents aged 12 years and older with severe alopecia areata at a recommended dose of 50 mg. Approval of Litfulo was granted to Pfizer.
Jun 27, 2023
0
1
Just a year after the U.S. Food and Drug Administration (FDA) approved the first treatment for severe alopecia areata, the federal agency has approved a second treatment for the disfiguring skin disease—both the result ...
Jun 27, 2023
0
15
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in ...
Jun 16, 2023
0
9
Medicare will soon cover a new class of Alzheimer's drugs if they receive full approval from the U.S. Food and Drug Administration, with some key limits.
Jun 2, 2023
0
14
